Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival

References

• Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1(1):34–45. doi:10.1038/3509400911900250
   PubMed Web of Science ®Google Scholar
• Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15(12):701–711. doi:10.1038/nrc401626563462
   PubMed Web of Science ®Google Scholar
• Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem. 2011;57(10):1366–1375. doi:10.1373/clinchem.2011.16597721956922
   PubMed Web of Science ®Google Scholar
• Devlin HL, Mudryj M. Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett. 2009;274(2):177–186. doi:10.1016/j.canlet.2008.06.00718657355
   PubMed Web of Science ®Google Scholar
• Watson PA, Chen YF, Balbas MD, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA. 2010;107(39):16759–16765. doi:10.1073/pnas.101244310720823238
   PubMed Web of Science ®Google Scholar
• Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer. 1999;6(4):503–519. doi:10.1677/erc.0.006050310730904
   PubMed Web of Science ®Google Scholar
• Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN Jr, Evans CP. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis. 2007;10(1):6–14. doi:10.1038/sj.pcan.450092217075603
   PubMed Web of Science ®Google Scholar
• Yuan TC, Veeramani S, Lin FF, et al. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer. 2006;13(1):151–167. doi:10.1677/erc.1.0104316601285
   PubMed Web of Science ®Google Scholar
• Kim J, Adam RM, Solomon KR, Freeman MR. Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology. 2004;145(2):613–619. doi:10.1210/en.2003-077214563701
   PubMed Web of Science ®Google Scholar
• Wang Q, Horiatis D, Pinski J. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. Int J Cancer. 2004;111(4):508–513. doi:10.1002/(ISSN)1097-021515239127
   PubMed Web of Science ®Google Scholar
• Bang YJ, Pirnia F, Fang WG, et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA. 1994;91(12):5330–5334. doi:10.1073/pnas.91.12.53308202489
   PubMed Web of Science ®Google Scholar
• Spiotto MT, Chung TDK. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate. 2000;42(2):88–98. doi:10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P10617865
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Cañas I, Juarranz MG, Collado B, et al. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K. Prostate. 2005;63(1):44–55. doi:10.1002/pros.2017315468165
   PubMed Web of Science ®Google Scholar
• Uysal-Onganer P, Kawano Y, Caro M, et al. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer. 2010;9:55. doi:10.1186/1476-4598-9-5520219091
   PubMed Web of Science ®Google Scholar
• Harris KS, Kerr BA. Prostate cancer stem cell markers drive progression, therapeutic resistance, and bone metastasis. Stem Cells Int. 2017;2017:8629234. doi:10.1155/2017/862923428690641
   PubMed Web of Science ®Google Scholar
• Graça I, Pereira-Silva E, Henrique R, Packham G, Crabb SJ, Jerónimo C. Epigenetic modulators as therapeutic targets in prostate cancer. Clin Epigenetics. 2016;8:98. doi:10.1186/s13148-016-0264-827651838
   PubMed Web of Science ®Google Scholar
• Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol. 2010;2010:479364. doi:10.1155/2010/47936420798865
   PubMed Web of Science ®Google Scholar
• Blaheta RA, Cinatl J. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev. 2002;22(5):492–511. doi:10.1002/(ISSN)1098-112812210556
   PubMed Web of Science ®Google Scholar
• Sidana A, Wang M, Shabbeer S, et al. Mechanism of growth inhibition of prostate cancer xenografts by valproic acid. J Biomed Biotechnol. 2012;2012:180363. doi:10.1155/2012/18036323093837
   PubMedGoogle Scholar
• Witt D, Burfeind P, von Hardenberg S, et al. Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. Carcinogenesis. 2013;34(5):1115–1124. doi:10.1093/carcin/bgt01923349020
   PubMed Web of Science ®Google Scholar
• Valentini A, Biancolella M, Amati F, et al. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line. Drug Metab Dispos. 2007;35:968–972. doi:10.1124/dmd.107.01466217371798
   PubMed Web of Science ®Google Scholar
• Frigo DE, McDonnell DP. Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Mol Cancer Ther. 2008;7(3):659–669. doi:10.1158/1535-7163.MCT-07-048018347151
   PubMed Web of Science ®Google Scholar
• Yam CH, Fung TK, Poon RY. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 2002;59(8):1317–1326. doi:10.1007/s00018-002-8510-y12363035
   PubMed Web of Science ®Google Scholar
• Stacey DW. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol. 2003;15(2):158–163. doi:10.1016/S0955-0674(03)00008-512648671
   PubMed Web of Science ®Google Scholar
• Xia Q, Sung J, Chowdhury W, et al. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 2006;66(14):7237–7244. doi:10.1158/0008-5472.CAN-05-048716849572
   PubMed Web of Science ®Google Scholar
• Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R, Carducci MA. Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate. 2007;67:1099–1110. doi:10.1002/(ISSN)1097-004517477369
   PubMed Web of Science ®Google Scholar
• Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S, Beppu T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res. 1994;214(1):189–197. doi:10.1006/excr.1994.12488082721
   PubMed Web of Science ®Google Scholar
• Yoshida M, Hoshikawa Y, Koseki K, Mori K, Beppu T. Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J Antibiot. 1990;43(9):1101–1106. doi:10.7164/antibiotics.43.11012211374
   PubMed Web of Science ®Google Scholar
• Nakano K, Mizuno T, Sowa Y, et al. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem. 1997;272(35):22199–22206. doi:10.1074/jbc.272.35.221999268365
   PubMed Web of Science ®Google Scholar
• Sambucetti LC, Fischer DD, Zabludoff S, et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem. 1999;274(49):34940–34947. doi:10.1074/jbc.274.49.3494010574969
   PubMed Web of Science ®Google Scholar
• Katsetos CD, Herman MM, Mork SJ. Class III β-tubulin in human development and cancer. Cell Motil Cytoskeleton. 2003;55(2):77–96. doi:10.1002/cm.v55:212740870
   PubMed Web of Science ®Google Scholar
• Katsetos CD, Kontogeorgos G, Geddes JF, et al. Differential distribution of the neuron-associated class III h-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med. 2000;124(4):535–544. doi:10.1043/0003-9985(2000)124<0535:DDOTNA>2.0.CO;210747310
   PubMed Web of Science ®Google Scholar
• Ploussard G, Terry S, Maillé P, et al. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res. 2010;70(22):9253–9264. doi:10.1158/0008-5472.CAN-10-144721045157
   PubMed Web of Science ®Google Scholar
• Cussenot O, Villette JM, Cochand-Priollet B, Berthon P. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Prostate Suppl. 1998;8:43–51.9690663
   PubMedGoogle Scholar
• Grobholz R, Griebe M, Sauer CG, Michel MS, Trojan L, Bleyl U. Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. Hum Pathol. 2005;36(5):562–570. doi:10.1016/j.humpath.2005.02.01915948124
   PubMed Web of Science ®Google Scholar
• Lehman JA, Gomez-Cambronero J. Molecular crosstalk between p70S6k and MAPK cell signaling pathways. Biochem Biophys Res Commun. 2002;293(1):463–469. doi:10.1016/S0006-291X(02)00238-312054624
   PubMed Web of Science ®Google Scholar
• Pon YL, Zhou HY, Cheung AN, Ngan HY, Wong AS. p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. Cancer Res. 2008;68(16):6524–6532. doi:10.1158/0008-5472.CAN-07-630218701475
   PubMed Web of Science ®Google Scholar
• Huang H, Tindall DJ. Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta. 2011;1813(11):1961–1964. doi:10.1016/j.bbamcr.2011.01.00721238503
   PubMed Web of Science ®Google Scholar
• Plas DR, Thompson CB. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem. 2003;278(14):12361–12366. doi:10.1074/jbc.M21306920012517744
   PubMed Web of Science ®Google Scholar
• Hao Y, Creson T, Zhang L, et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci. 2004;24(29):6590–6599. doi:10.1523/JNEUROSCI.5747-03.200415269271
   PubMed Web of Science ®Google Scholar
• Yadav SS, Li J, Stockert JA, et al. Induction of neuroendocrine differentiation in prostate cancer cells by dovitinib (TKI-258) and its therapeutic implications. Transl Oncol. 2017;10(3):357–366. doi:10.1016/j.tranon.2017.01.01128342996
   PubMed Web of Science ®Google Scholar